The outcome of patients with recurrent/metastatic cervical cancer (R/M CC) is poor, with a 5-year survival rate of only 10%-20%. Recent advances in immunotherapy renewed its interest in R/M CC treatment. It has been suggested that cadonilimab, a novel bispecific antibody targeting programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), significantly improved the survival outcomes of the R/M CC.
View Article and Find Full Text PDFHaggite-structured VO(OH) is prepared via a one-step reduction of VO in a mixture of guaiacol and methanol. Guaiacol delays the overreduction of Haggite to VO. The time window for the stable existence of the Haggite phase is enlarged at low temperature.
View Article and Find Full Text PDFThe tunable transformation of renewable furfural with aliphatic alcohols in the presence of O2 is developed. Based on a nano Au catalyst and potassium carbonate, a 91.8% yield of methyl 2-furoate with 98.
View Article and Find Full Text PDF